imatinib mesylate has been researched along with Arthritis, Spinal in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baeten, D; Caňete, JD; Gofita, I; Noordenbos, T; Tak, PP; van de Sande, M; Yeremenko, N | 1 |
| Eklund, KK; Kautiainen, H; Leirisalo-Repo, M; Reitamo, S; Remitz, A | 1 |
1 trial(s) available for imatinib mesylate and Arthritis, Spinal
| Article | Year |
|---|---|
Three months treatment of active spondyloarthritis with imatinib mesylate: an open-label pilot study with six patients.
Topics: Adult; Antirheumatic Agents; Benzamides; Humans; Imatinib Mesylate; Middle Aged; Pilot Projects; Piperazines; Pyrimidines; Severity of Illness Index; Spondylarthritis; Treatment Outcome | 2006 |
1 other study(ies) available for imatinib mesylate and Arthritis, Spinal
| Article | Year |
|---|---|
Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis.
Topics: Adult; Aged; Arthritis, Psoriatic; Arthritis, Rheumatoid; Benzamides; Cell Degranulation; Cells, Cultured; Female; Gene Expression; Humans; Imatinib Mesylate; Interleukin-17; Male; Mast Cells; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA, Messenger; Spondylarthritis; Synovial Fluid; Synovial Membrane; Synovitis; Young Adult | 2012 |